References:
1. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
2. Morrell M et al. Antimicrob Agents Chemother. 2005;49(9):3640–3645.
3. Bassetti M et al. Crit Care. 2014;18:458.
4. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
5. Tashiro M et al. J Infect Chemother. 2021;27:1471–1476.
6. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
7. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
8. Góralska K et al. Infection. 2018;46:443–459.
9. Rüping MJGT et al. Drugs. 2008;68:1941–1962.
10. Kuse E-R et al. Lancet. 2007;369(9572):1519–1527.
11. De Pascale G et al. Curr Opin Crit Care. 2015;21:421–429.
12. Gangneux JP et al. J Mycol Méd. 2020;30:100971.
13. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
14. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
15. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
16. Kollef M et al. Clin Infect Dis. 2012;54:1739–1746.
17. IDSA guidelines for the management of candidiasis (2016). Pappas PG et al.
Clin Infect Dis. 2016;62(4):e1–e50.
18. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
19. Falci DR et al. Mycoses. 2015;58:104–112.
20. Adler-Moore JP and Proffitt RT. J Antimicrob Chemother. 2002;49
(Suppl. 1):21–30.
21. Keady S et al. EJHP Practice. 2010;16(3):78–80.
22. Stone NR et al. Drugs. 2016;76(4):485–500.
23. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
24. Ullmann A et al. Clin Infect Dis. 2006;43:e29–e38.
25. Wingard JT et al. Clin Infect Dis. 2000;31:1155–1163.
26. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30:51–83.
27. Taccone FS et al. Crit Care. 2015;9:7.
28. Cornely OA et al. Mycoses. 2011;54(5):e449–e455.
29. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
30. Mercier T et al. Crit Care. 2020;24:642.
References:
1. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
16. Kollef M et al. Clin Infect Dis. 2012;54:1739–1746.
17. IDSA guidelines for the management of candidiasis (2016). Pappas PG et al. Clin Infect Dis. 2016;62(4):e1–e50.
18. Walsh TJ et al. N Engl J Med. 1999;340(10):764–771.
19. Falci DR et al. Mycoses. 2015;58:104–112.
20. Adler-Moore JP and Proffitt RT. J Antimicrob Chemother. 2002;49(Suppl. 1):21–30.
21. Keady S et al. EJHP Practice. 2010;16(3):78–80.
22. Stone NR et al. Drugs. 2016;76(4):485–500.
23. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
24. Ullmann A et al. Clin Infect Dis. 2006;43:e29–e38.
25. Wingard JT et al. Clin Infect Dis. 2000;31:1155–1163.
26. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30:51–83.
27. Taccone FS et al. Crit Care. 2015;9:7.
28. Cornely OA et al. Mycoses. 2011;54(5):e449–e455.
29. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
30. Mercier T et al. Crit Care. 2020;24:642.
2. Morrell M et al. Antimicrob Agents Chemother. 2005;49(9):3640–3645.
3. Bassetti M et al. Crit Care. 2014;18:458.
4. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
5. Tashiro M et al. J Infect Chemother. 2021;27:1471–1476.
6. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
7. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
8. Góralska K et al. Infection. 2018;46:443–459.
9. Rüping MJGT et al. Drugs. 2008;68:1941–1962.
10. Kuse E-R et al. Lancet. 2007;369(9572):1519–1527.
11. De Pascale G et al. Curr Opin Crit Care. 2015;21:421–429.
12. Gangneux JP et al. J Mycol Méd. 2020;30:100971.
13. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref. [Last accessed: March 2023].
14. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
15. Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179–185.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare
professionals only. It contains information about Gilead products, educational materials on therapy areas,
and professional resources.
Prescribing information for Ambisome